Intermittent Subcutaneous Apomorphine Therapy for ‘Off’ Episodes in Parkinson’s DiseaseA 6-Month Open-Label Study

被引：0
|
作者：
Richard M. Trosch
Dee Silver
Peter B. Bottini
机构：
[1] The Parkinson’s Disease and Movement Disorders Center,
[2] Coastal Neurological Group,undefined
[3] Mylan Laboratories Inc.,undefined
来源：
CNS Drugs | 2008年 / 22卷
关键词：
Apomorphine; Evaluation Visit; Dopamine Receptor Agonist; Motor Complication; Subcutaneous Apomorphine;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Purpose: The outpatient follow-up phase of the apomorphine (APO) 303 study assessed the long-term efficacy and safety of intermittent subcutaneous apomorphine for ‘off’ episodes in patients with advanced Parkinson’s disease.
引用
收藏
页码：519 / 527
页数：8
相关论文
共 50 条
  • [1] Intermittent subcutaneous apomorphine therapy for 'off' episodes in Parkinson's disease - A 6-month open-label study
    Trosch, Richard M.
    Silver, Dee
    Bottini, Peter B.
    CNS DRUGS, 2008, 22 (06) : 519 - 527
  • [2] Apomorphine Sublingual Film Compared with Subcutaneous Apomorphine for OFF Episodes in Parkinson's Disease: An Open-Label, Randomized, Crossover Study
    Stocchi, Fabrizio
    Rascol, Olivier
    Poewe, Werner
    Chaudhuri, K. Ray
    Kassubek, Jan
    Lopez Manzanares, Lydia
    Zhang, Yi
    Bowling, Alyssa
    Pappert, Eric
    Wu, Stacy
    JOURNAL OF PARKINSONS DISEASE, 2023, 13 (08) : 1329 - 1342
  • [3] A 6-month open-label trial of tolcapone in Parkinson's disease
    Charles, PD
    Davis, TL
    SaintHilaire, MH
    Trosch, RM
    LeWitt, P
    Kurth, MC
    Pedder, S
    Dorflinger, E
    ANNALS OF NEUROLOGY, 1997, 42 (03) : M64 - M64
  • [4] Open-label titration of apomorphine sublingual film in patients with Parkinson's disease and "OFF" episodes
    Hui, Jennifer S.
    Fox, Susan H.
    Neeson, William
    Bhargava, Parul
    Pappert, Eric
    Blum, David
    Navia, Bradford
    PARKINSONISM & RELATED DISORDERS, 2020, 79 : 110 - 116
  • [5] Open-Label Study Assessment of Safety and Adverse Effects of Subcutaneous Apomorphine Injections in Treating "Off" Episodes in Advanced Parkinson Disease
    LeWitt, Peter A.
    Ondo, William G.
    Van Lunen, Brenda
    Bottini, Peter B.
    CLINICAL NEUROPHARMACOLOGY, 2009, 32 (02) : 89 - 93
  • [6] Pharmacokinetics and Comparative Bioavailability of Apomorphine Sublingual Film and Subcutaneous Apomorphine Formulations in Patients with Parkinson’s Disease and “OFF” Episodes: Results of a Randomized, Three-Way Crossover, Open-Label Study
    Felix Agbo
    Stuart H. Isaacson
    Ramon Gil
    Yu-Yuan Chiu
    Scott J. Brantley
    Parul Bhargava
    Bradford Navia
    Neurology and Therapy, 2021, 10 : 693 - 709
  • [7] Pharmacokinetics and Comparative Bioavailability of Apomorphine Sublingual Film and Subcutaneous Apomorphine Formulations in Patients with Parkinson's Disease and "OFF'' Episodes: Results of a Randomized, Three-Way Crossover, Open-Label Study
    Agbo, Felix
    Isaacson, Stuart H.
    Gil, Ramon
    Chiu, Yu-Yuan
    Brantley, Scott J.
    Bhargava, Parul
    Navia, Bradford
    NEUROLOGY AND THERAPY, 2021, 10 (02) : 693 - 709
  • [8] Intermittent subcutaneous apomorphine therapy in Parkinson's disease
    Factor, SA
    NEUROLOGY, 2004, 62 (06) : S12 - S17
  • [9] Onset of action of intermittent subcutaneous apomorphine in the treatment of "off" episodes in patients with advanced Parkinson's disease
    Hull, KL
    Gutman, L
    MOVEMENT DISORDERS, 2004, 19 : S216 - S216
  • [10] SAFETY OF SUBCUTANEOUS BELIMUMAB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A 6-MONTH OPEN-LABEL EXTENSION STUDY
    Doria, A.
    Stohl, W.
    Schwarting, A.
    Scheinberg, M.
    Hammer, A.
    Kleoudis, C.
    Groark, J.
    Fox, N. L.
    Roth, D.
    Bass, D.
    Gordon, D.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 861 - 861
12345